Sponsor content
335 result(s) found, displaying 21 to 30
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DATROWAY datopotamab deruxtecan 100 mg powder for injection vial.
-
Sep-2025Prescription medicine evaluationActive ingredient: budesonide, formoterol fumarate dihydrate, glycopyrronium bromide.
-
Sep-2025Prescription medicine evaluationActive ingredient: tezepelumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Tezspire tezepelumab 210 mg in 1.91mL solution for Injection prefilled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Tezspire, tezepelumab 210 mg in 1.91mL solution for Injection prefilled syringe.
-
Australian public assessment report (AusPar)DATROWAY (datopotamab deruxtecan) as a monotherapy is for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine therapy and at least one additional systemic therapy in the locally advanced or metastatic setting.
-
Jul-2025Prescription medicine evaluationActive ingredient: camizestrant.
-
-
Cancellation by sponsorRequested by AstraZeneca Pty Ltd